Back to top
more

Masimo (MASI)

(Real Time Quote from BATS)

$139.93 USD

139.93
30,973

-0.01 (-0.01%)

Updated Oct 9, 2024 10:48 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Masimo (MASI) Boosts O3 Platform With Three New Indices

Masimo (MASI) announced the development of three additional indices for O3 Regional Oximetry, thereby improving the O3 platform.

Here's Why Investors Should Retain Accuray (ARAY) Stock Now

Accuray (ARAY) slashes fiscal 2020 revenue guidance owing to tariffs in China.

Masimo (MASI) Introduces Pathway, Boosts Patient Monitoring

Masimo's (MASI) new feature, Pathway, is likely to help clinicians simplify their workflow associated with newborn resuscitation, thereby improving patient monitoring.

Is Masimo (MASI) Stock Outpacing Its Medical Peers This Year?

Is (MASI) Outperforming Other Medical Stocks This Year?

HealthEquity (HQY) Earnings & Revenues Beat Estimates in Q2

HealthEquity (HQY) gains from solid segmental contributions in second-quarter fiscal 2020.

HealthEquity Acquires WageWorks, To Make Notable Investments

HealthEquity (HQY) expects to complete its $80-100 million investment program within 24-36 months from now.

Cooper Companies (COO) Q3 Earnings Beat, Revenues Rise Y/Y

Cooper Companies (COO) gains from solid segmental contributions in fiscal Q3.

Varian's ProBeam Compact System Picked by University of Miami

Varian (VAR) sees notable developments in its Proton Solutions business of late.

DexCom (DXCM) Scales 52-Week High: What's Driving the Stock?

DexCom (DXCM) has various favorable factors to maintain the current high.

Has Masimo (MASI) Outpaced Other Medical Stocks This Year?

Is (MASI) Outperforming Other Medical Stocks This Year?

Is Masimo (MASI) Stock Outpacing Its Medical Peers This Year?

Is (MASI) Outperforming Other Medical Stocks This Year?

DexCom (DXCM) Hits 52-Week High, Can the Run Continue?

DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Masimo (MASI) Earnings and Revenues Beat Estimates in Q2

Buoyed by a solid second quarter, Masimo (MASI) raises its 2019 guidance.

Masimo (MASI) Q2 Earnings and Revenues Beat Estimates

Masimo (MASI) delivered earnings and revenue surprises of 4.11% and 3.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Medical Products' Earnings Roster for Jul 31: MCK, HOLX & More

Solid growth in emerging markets is expected to be an added positive this earnings season.

Masimo (MASI) to Report Q2 Earnings: What's in the Offing?

Masimo's (MASI) recent developments likely to show on second-quarter results.

Masimo (MASI) Q2 Earnings Preview: What's in the Cards?

Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Masimo (MASI) Hits a 52-Week High on Solid Growth Drivers

Masimo (MASI) gains from expansion of product portfolio and recent regulatory approvals.

Here's Why You Should Add Bruker (BRKR) to Your Portfolio

Investor confidence in Bruker stock (BRKR) is high on substantial potential of MALDI Biotyper.

Here's Why You Should Buy Masimo (MASI) Stock Right Now

Masimo (MASI) receives FDA clearance for its O3 Regional Oximetry for utilization on neonatal and infant patients.

Urmimala Biswas headshot

Near-Term Outlook for Medical Instruments Industry Bleak

Complex regulatory hurdles come in the way of any infrastructural or technology growth in the Medical Instruments space.

DaVita Divests DMG to Optum, Boosts Kidney Care Services

The divestment of DMG boosts DaVita's (DVA) core Kidney Care business.

Here's Why You Should Hold PerkinElmer (PKI) Stock for Now

PerkinElmer (PKI) raises earnings per share guidance for 2019.

Merit Medical Acquires Brightwater Medical for $35 Million

The Brightwater Medical-acquisition broadens Merit Medical's (MMSI) product offerings.

Here's Why You Should Hold Baxter International (BAX) for Now

Baxter (BAX) expects its bottom line to rise in the second quarter of 2019, courtesy to Renal Care and Clinical Nutrition businesses.